
|Articles|May 31, 2015
Effect of Age and Lenvatinib on OS in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.
Advertisement
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with131I
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
2
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
3
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
4
COSMIC-313 Trial: KIM-1 Associated With Clinical Outcomes in Advanced RCC
5







































